BR112017011685A2 - composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas - Google Patents

composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas

Info

Publication number
BR112017011685A2
BR112017011685A2 BR112017011685-5A BR112017011685A BR112017011685A2 BR 112017011685 A2 BR112017011685 A2 BR 112017011685A2 BR 112017011685 A BR112017011685 A BR 112017011685A BR 112017011685 A2 BR112017011685 A2 BR 112017011685A2
Authority
BR
Brazil
Prior art keywords
hepe
treating
methods
compositions
preventing fibrosis
Prior art date
Application number
BR112017011685-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Rowe Jonathan
Duffy Kevin
Climax John
Original Assignee
Afimmune Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afimmune Limited filed Critical Afimmune Limited
Publication of BR112017011685A2 publication Critical patent/BR112017011685A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112017011685-5A 2014-12-02 2015-12-02 composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas BR112017011685A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086535P 2014-12-02 2014-12-02
US62/086,535 2014-12-02
PCT/US2015/063488 WO2016090030A1 (en) 2014-12-02 2015-12-02 Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same

Publications (1)

Publication Number Publication Date
BR112017011685A2 true BR112017011685A2 (pt) 2018-01-02

Family

ID=56092410

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017011685-5A BR112017011685A2 (pt) 2014-12-02 2015-12-02 composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas

Country Status (17)

Country Link
US (1) US10363235B2 (enExample)
EP (2) EP3226873B1 (enExample)
JP (2) JP6986445B2 (enExample)
KR (1) KR20170102879A (enExample)
CN (2) CN107206008A (enExample)
AU (2) AU2015358512B2 (enExample)
BR (1) BR112017011685A2 (enExample)
CA (1) CA2968980A1 (enExample)
ES (1) ES2900593T3 (enExample)
IL (2) IL252431B (enExample)
MA (1) MA41120A (enExample)
MX (2) MX382116B (enExample)
PH (1) PH12017501022B1 (enExample)
RU (2) RU2721555C2 (enExample)
SG (2) SG10202010594WA (enExample)
WO (1) WO2016090030A1 (enExample)
ZA (2) ZA201704463B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
CN105899485B (zh) 2013-11-15 2018-10-19 尊严科学有限公司 多不饱和羟基脂肪酸的药学上可接受的盐
US20150196521A1 (en) * 2014-01-10 2015-07-16 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
CN113893240A (zh) * 2015-01-16 2022-01-07 艾菲穆恩有限公司 包含15-hepe的组合物和其使用方法
CN113896628A (zh) 2015-05-13 2022-01-07 Ds生物制药有限公司 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
KR20180094516A (ko) * 2015-12-18 2018-08-23 애피뮨 리미티드 15-hepe를 포함하는 조성물 및 이를 사용하는 방법
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180671B1 (en) * 1998-03-10 2001-01-30 Beth Israel Deaconess Medical Center, Inc. Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
WO2001049282A2 (en) * 2000-01-06 2001-07-12 Martek Biosciences Corporation Therapeutic preparations of highly unsaturated fatty acids
ATE504557T1 (de) 2000-02-16 2011-04-15 Brigham & Womens Hospital Aspirin-ausgelöste lipidmediatoren
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
WO2005063231A2 (en) 2003-12-31 2005-07-14 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof
US20050239889A1 (en) 2004-04-26 2005-10-27 Jean Gosselin In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
WO2008021192A2 (en) * 2006-08-08 2008-02-21 Lipomics Technologies, Inc. Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
US8042070B2 (en) * 2007-10-23 2011-10-18 International Business Machines Corporation Methods and system for analysis and management of parametric yield
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
US20110105510A1 (en) 2008-06-17 2011-05-05 Hiroshi Ishikawa Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
WO2010120880A1 (en) * 2009-04-14 2010-10-21 Vertex Pharmaceuticals Incorporated Treatment of liver diseases with a caspase inhibitor
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US10154977B2 (en) 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) * 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
BR112014006220A2 (pt) * 2011-09-16 2017-04-11 Galectin Therapeutics Inc composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
SG11201401629XA (en) 2011-10-19 2014-05-29 Dignity Sciences Ltd Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
US8293790B2 (en) * 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
JP2015500639A (ja) 2011-11-29 2015-01-08 ディグニティ サイエンシス リミテッド ２０−炭素脂肪酸を含む組成物ならびにその製造方法および使用方法
CA2859573A1 (en) * 2011-12-16 2013-06-20 Tarix Pharmaceuticals Ltd. Angiotensins for treatment of fibrosis
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
EP4205546A1 (en) 2012-05-10 2023-07-05 Solutex NA LLC Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
KR20180094516A (ko) 2015-12-18 2018-08-23 애피뮨 리미티드 15-hepe를 포함하는 조성물 및 이를 사용하는 방법

Also Published As

Publication number Publication date
IL252431A0 (en) 2017-07-31
IL287983A (en) 2022-01-01
KR20170102879A (ko) 2017-09-12
PH12017501022B1 (en) 2022-02-16
EP3226873A1 (en) 2017-10-11
AU2015358512A1 (en) 2017-07-20
EP3988101A1 (en) 2022-04-27
JP2022031813A (ja) 2022-02-22
MA41120A (fr) 2017-10-10
PH12017501022A1 (en) 2017-11-27
MX2021005080A (es) 2021-06-15
RU2017122758A3 (enExample) 2019-06-13
US10363235B2 (en) 2019-07-30
AU2015358512B2 (en) 2021-02-18
EP3226873B1 (en) 2021-10-27
RU2020115523A (ru) 2021-01-27
CN107206008A (zh) 2017-09-26
SG11201704495VA (en) 2017-06-29
US20160184252A1 (en) 2016-06-30
RU2017122758A (ru) 2019-01-09
ES2900593T3 (es) 2022-03-17
MX382116B (es) 2025-03-13
EP3226873A4 (en) 2018-08-08
CA2968980A1 (en) 2016-06-09
WO2016090030A1 (en) 2016-06-09
CN112245419A (zh) 2021-01-22
HK1245101A1 (zh) 2018-08-24
AU2021203189A1 (en) 2021-06-10
ZA201804380B (en) 2021-03-31
JP6986445B2 (ja) 2021-12-22
ZA201704463B (en) 2018-11-28
IL252431B (en) 2021-12-01
SG10202010594WA (en) 2020-12-30
RU2721555C2 (ru) 2020-05-20
JP2017536380A (ja) 2017-12-07
MX2017007000A (es) 2017-12-07

Similar Documents

Publication Publication Date Title
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
BR112017006664A2 (pt) terapias de combinação
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
MX2017012380A (es) Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112017011215A2 (pt) partículas de distribuição de pró-flavorizante
FR3021319B1 (fr) Peptides, compositions les comprenant et utilisations notamment cosmetiques
BR112016026378A2 (pt) formulações e métodos para tratamento com queratina
DK3121175T3 (da) 1,3-benzodioxolderivater som ezh1- og/eller ezh2-hæmmere
MX375352B (es) Reguladores de nrf2.
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
BR112017011685A2 (pt) composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas
PT3200582T (pt) Composições, kits e métodos para induzir citorresistência adquirida com utilização de indutores de proteínas de stress
MA40998A (fr) Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
EP3052510A4 (en) Methods and compositions for treating and/or preventing mucositis
BR112017008799A2 (pt) composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal
BR112017027721A2 (pt) formulação de alta concentração
BR112017007414A2 (pt) combinações compreendendo siponimod e laquinimod para o tratamento de esclerose múltipla
BR112017009000A2 (pt) apilimod para uso no tratamento de melanoma
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
BR112017012818A2 (pt) fixador.
FR3029915B1 (fr) Tripeptides, compositions les comprenant et utilisations notamment cosmetiques
UY36292A (es) Compuestos de tetrahidroquinolina para su uso como inhibidores de bromodominios
WO2016020210A8 (en) Factor viii formulation

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements